Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Envisioning Low-Dose Tarlatamab.
Journal: JTO clinical and research reports
Published: August 27, 2026
Baseline IL-6, IL-8, IFN-ω, and perforin as prognostic biomarkers in immune checkpoint inhibitor-treated metastatic non-small cell lung cancer.
Journal: Translational lung cancer research
Published: April 11, 2026
ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.
Journal: Journal of neuro-oncology
Published: September 16, 2022
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Journal: Journal for immunotherapy of cancer
Published: January 14, 2022
Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations-An Exemplar in Brain Tumors.
Journal: JCO clinical cancer informatics
Published: September 23, 2021
Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review.
Journal: Neuro-oncology practice
Published: October 05, 2020
Nivolumab-associated nausea and vomiting as an immune adverse event.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 17, 2017
Extracranial metastasis of gliobastoma: Three illustrative cases and current review of the molecular pathology and management strategies.
Journal: Molecular and clinical oncology
Published: November 13, 2014
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
Journal: The oncologist
Published: September 28, 2013
Phase I trial of pomalidomide given for patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: March 02, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026